Demand for injectable medicines is rising — manufacturing capacity is becoming the key challenge

Demand for injectable medicines is rising — manufacturing capacity is becoming the key challenge

Demand for GLP-1 medicines, biologics and other injectable therapies has grown rapidly in recent years. This also increases the need for injection pens, autoinjectors, syringes and other drug-delivery devices.

The challenge is that production cannot be expanded overnight. Large-scale manufacturing requires specialised equipment, cleanrooms, automated production lines, quality systems and validated processes. Building new capacity can take 18–24 months or longer.

Why does this matter? Expanding manufacturing capacity in advance can help companies produce enough devices, reduce the risk of shortages and supply disruptions, and ensure that patients receive their treatments on time.

For pharmaceutical companies, the focus is therefore no longer only on developing new medicines. They also need to plan how those medicines and delivery devices can be produced reliably and at large scale for growing numbers of patients.

Source: Pharmaceutical Technology / Quvara Medical